10 Jun 2016
New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improves Signs and Symptoms of Disease
London, United Kingdom, 8 June, 2016 – Janssen Research & Development, LLC (Janssen) announced today results from a pivotal Phase 3 study evaluating…
2 Jun 2016
Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis from Two Phase III Studies for Anamorelin in Cachectic Patients with Non-Small Cell Lung Cancer (NSCLC)
Lugano, Switzerland, June 1, 2016 – Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announces that it will present…